Blue chip biopharma equities closed out the month of November on a high note with the BioWorld Biopharmaceutical index up almost 6 percent, which appeared to have helped erase the memories of a tough October that saw the index fall 10 percent in the wake of a general market correction. (See BioWorld Insight, Nov. 5, 2018.)